what are gip and glp 1 receptors Tirzepatide's Unique Mechanism of Action - GIP/GLP-1 Dual Agonist GLP1-GIP receptor co-agonists: a promising

El descubrimiento de su funcin ha revolucionado el tratamiento de la diabetes tipo 2 y la obesidad, dando lugar a medicamentos innovadores que imitan su accin

A plateau and maintenance can look similar on the scale, but they are not the same

With all that said, the side effects do not mean that GLP-1s are unsafe

In one study, patients regained about two-thirds of the weight they had lost just one year after stopping semaglutide treatment, and their cardiometabolic risk markers (blood sugar, cholesterol, etc.) reverted toward baseline (source)

In consideration of the reduced compliance of peptide GLP-1 receptor agonists due to subcutaneous injection, oral micromolecular GLP-1 receptor agonists such as orforglipron have already in clinical trials, which can reduce body weight and improve cardiac metabolism in adults with obesity (Wharton et al 2023) (Fig